Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates

Publisher: La Merie Publishing
Pages: 22
Format: PDF
Product Line:
Monthly Tracking Reports
Product Code: LMBT0006
Release Date: October of 2016

200.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Anti-Her2 Antibody-Drug Conjugates in:

September 2016 R&D and Business Tracker for Antibody-Drug Conjugates

This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.

Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.

The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:


R&D and Technology Tracker

  • Pipeline changes
  • Regulatory news
  • Technology validations
  • Manufacturing news

Business Tracker for:

  • Company updates
  • Collaboration
  • Licensing
  • Merger & acquisitions
  • Financing

Clinical Trial Tracker
Scientific Publication Tracker
Featured ADC Profile: MEDI4276
Featured Company Profile: NBE Therapeutics
Featured Target Pipeline: Anti-Her2 Antibody-Drug Conjugates

Information about the anti-Her2 ADC pipeline is provided in a tabular format and fully referenced.

Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.

Contact us at publishing@lamerie.com to discuss your needs and our ideas of fulfilling them.


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top